Peginterferon Alfa-2b and Ribavirin for 12 vs. 24 Weeks in HCV Genotype 2 or 3
Top Cited Papers
Open Access
- 23 June 2005
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 352 (25), 2609-2617
- https://doi.org/10.1056/nejmoa042608
Abstract
We hypothesized that in patients with hepatitis C virus (HCV) genotype 2 or 3 in whom HCV RNA is not detectable after 4 weeks of therapy, 12 weeks of treatment is as effective as 24 weeks.Keywords
This publication has 16 references indexed in Scilit:
- Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis CAnnals of Internal Medicine, 2004
- Sustained virological response after a short course of treatment with interferon and ribavirin in two chronic hepatitis C patientsJournal of Hepatology, 2003
- Adherence to combination therapy enhances sustained response in genotype-1–infected patients with chronic hepatitis CGastroenterology, 2002
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2002
- Hepatitis C infection and the patient with end-stage renal diseaseHepatology, 2002
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialThe Lancet, 2001
- Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon α2aGastroenterology, 2001
- Differences in Viral Dynamics between Genotypes 1 and 2 of Hepatitis C VirusThe Journal of Infectious Diseases, 2000
- Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α TherapyScience, 1998
- Quantification of the initial decline of serum hepatitis c virus RNA and response to interferon alfaHepatology, 1998